{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:36:38Z","timestamp":1785418598205,"version":"3.56.0"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA279968"],"award-info":[{"award-number":["R01CA279968"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM135095"],"award-info":[{"award-number":["T32GM135095"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>PD-1\/PD-L1 immune checkpoint inhibitor (ICI)-based combination regimens have transformed metastatic urothelial cancer treatment. However, phase III trials of these regimens have shown varied results. We sought to understand these differences by assessing whether these combinations are synergistic, additive, or less-than-additive, which is crucial for translational research and clinical development. We systematically identified five randomized phase III trials of ICI-based combinations for metastatic urothelial carcinoma and tested whether progression-free survival (PFS) distributions of combinations were as predicted by a null hypothesis of additivity, defined as the sum of PFS durations of individual drugs. For KEYNOTE-361 and IMvigor130, which allowed cisplatin or carboplatin, we evaluated platinum-specific predictions. We found that PFS distributions in trials adding PD-1\/PD-L1 ICI to enfortumab vedotin (EV-302), gemcitabine plus cisplatin (CheckMate 901), or CTLA-4 blockade (DANUBE) were statistically indistinguishable from additivity. In trials using choice of cisplatin or carboplatin (KEYNOTE-361, IMvigor130), ICI combinations with cisplatin\u2013gemcitabine yielded additive PFS, whereas ICI combinations with carboplatin\u2013gemcitabine yielded less-than-additive PFS, indicating that carboplatin blunts the potential benefits of PD-1\/PD-L1 inhibitors. The predictable success of EV-302 and CheckMate 901 demonstrate that substantial improvements in clinical outcomes can be achieved by additive combinations of individually effective agents. Overall, modeling PFS from single-agent data could have anticipated most contemporary phase III trial outcomes, potentially informing rational trial design and prioritization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Practice-changing PD-1\/PD-L1 immune checkpoint combinations in urothelial cancer show additive, not synergistic, efficacy in phase III trials. However, carboplatin was significantly less-than-additive with immunotherapy, helping explain negative results of KEYNOTE-361 and IMvigor130.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0157","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T03:53:37Z","timestamp":1780286017000},"page":"1447-1454","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2315-6692","authenticated-orcid":false,"given":"Noah M.","family":"Schlachter","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0130frc33","id-type":"ROR","asserted-by":"publisher"}],"name":"University of North Carolina at Chapel Hill 1 Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center, , Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9244-6672","authenticated-orcid":false,"given":"Eric J.","family":"Miller","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Medicine, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-0346","authenticated-orcid":false,"given":"Jonathan F.","family":"Anker","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Medicine, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-9378","authenticated-orcid":false,"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04a9tmd77","id-type":"ROR","asserted-by":"publisher"}],"name":"Icahn School of Medicine at Mount Sinai 2 Department of Medicine, Tisch Cancer Institute, , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-7028","authenticated-orcid":false,"given":"Adam C.","family":"Palmer","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0130frc33","id-type":"ROR","asserted-by":"publisher"}],"name":"University of North Carolina at Chapel Hill 1 Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center, , Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"2026061906013671800_bib1","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2026061906013671800_bib2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"2026061906013671800_bib3","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026061906013671800_bib4","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"2026061906013671800_bib5","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026061906013671800_bib6","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2026061906013671800_bib7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.trecan.2022.06.009","article-title":"Drug independence and the curability of cancer by combination chemotherapy","volume":"8","author":"Pomeroy","year":"2022","journal-title":"Trends Cancer"},{"key":"2026061906013671800_bib8","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s43018-023-00667-z","article-title":"Additivity predicts the efficacy of most approved combination therapies for advanced cancer","volume":"4","author":"Hwangbo","year":"2023","journal-title":"Nat Cancer"},{"key":"2026061906013671800_bib9","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026061906013671800_bib10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"2026061906013671800_bib11","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061906013671800_bib12","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026061906013671800_bib13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061906013671800_bib14","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"2026061906013671800_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026061906013671800_bib16","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/cncr.35179","article-title":"Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1\/programmed death ligand 1 blockade","volume":"130","author":"Miller","year":"2024","journal-title":"Cancer"},{"key":"2026061906013671800_bib17","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O\u2019Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026061906013671800_bib18","doi-asserted-by":"crossref","first-page":"baab037","DOI":"10.1093\/database\/baab037","article-title":"KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials","volume":"2021","author":"Fell","year":"2021","journal-title":"Database (Oxford)"},{"key":"2026061906013671800_bib19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41467-022-28410-9","article-title":"Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects","volume":"13","author":"Plana","year":"2022","journal-title":"Nat Commun"},{"key":"2026061906013671800_bib20","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of &gt;2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"2026061906013671800_bib21","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1158\/1078-0432.CCR-14-0521","article-title":"Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee","volume":"20","author":"Paller","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026061906013671800_bib22","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1093\/annonc\/mdr608","article-title":"How valid are claims for synergy in published clinical studies?","volume":"23","author":"Ocana","year":"2012","journal-title":"Ann Oncol"},{"key":"2026061906013671800_bib23","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1038\/s41467-020-19563-6","article-title":"Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action","volume":"11","author":"Ling","year":"2020","journal-title":"Nat Commun"},{"key":"2026061906013671800_bib24","doi-asserted-by":"crossref","first-page":"101393","DOI":"10.1016\/j.xcrm.2024.101393","article-title":"Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer","volume":"5","author":"Galsky","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026061906013671800_bib25","doi-asserted-by":"crossref","first-page":"357.e11","DOI":"10.1016\/j.urolonc.2023.03.012","article-title":"Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced\/metastatic urothelial carcinoma by cisplatin-eligibility","volume":"41","author":"Morgans","year":"2023","journal-title":"Urol Oncol"},{"key":"2026061906013671800_bib26","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"2026061906013671800_bib27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-21-2275","article-title":"Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors","volume":"28","author":"Palmer","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026061906013671800_bib28","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.eururo.2019.05.037","article-title":"Programmed death-1 or programmed death ligand-1 blockade in patients with platinum-resistant metastatic urothelial cancer: a systematic review and meta-analysis","volume":"76","author":"Niglio","year":"2019","journal-title":"Eur Urol"},{"key":"2026061906013671800_bib29","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1056\/NEJMc1716612","article-title":"Hazards of hazard ratios - deviations from model assumptions in immunotherapy","volume":"378","author":"Alexander","year":"2018","journal-title":"N Engl J Med"},{"key":"2026061906013671800_bib30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.21.01862","article-title":"Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma","volume":"40","author":"Zhao","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026061906013671800_bib31","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.3390\/cancers14071735","article-title":"Organ-specific and mixed responses to pembrolizumab in patients with unresectable or metastatic urothelial carcinoma: a multicenter retrospective study","volume":"14","author":"Shimizu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026061906013671800_bib32","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.3390\/ijerph18052600","article-title":"Multi-drug featurization and deep learning improve patient-specific predictions of adverse events","volume":"18","author":"Anastopoulos","year":"2021","journal-title":"Int J Environ Res Public Health"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0157\/3799718\/crc-26-0157.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1447\/3804278\/crc-26-0157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/6\/1447\/3804278\/crc-26-0157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:01:45Z","timestamp":1781863305000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/6\/1447\/785841\/Additivity-Not-Synergy-Underlies-the-Efficacy-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0157","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32743830","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743842","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743854","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743833","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743851","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743827","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743839","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743845","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743857","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743824","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32743836","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8547810","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}